SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MEDX ... anybody following?
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2240 62 0 MEDX
Emcee:  Ed Offstein Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2140Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories SigIcebrg-4/21/2009
2139Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at AnnualIcebrg-4/20/2009
2138Programmed death-1 as a factor in immune exhaustion and activation in HIV infectIcebrg-4/19/2009
2137Medarex to Receive Milestone Payment for Approval of SIMPONI(TM) for the TreatmeIcebrg-4/14/2009
2136Celldex Therapeutics Enhances Immunotherapy Platform with Acquisition of ExclusiIcebrg-4/9/2009
2135What a huge unmet market for treating sepsis. If the PD1/PD1-L antibody is efTettra-4/1/2009
2134PD-1 expression by macrophages plays a pathologic role in altering microbial cleIcebrg-4/1/2009
2133Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia onLJM-3/31/2009
2132Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and AutoIcebrg-3/26/2009
2131Controlling cancer by blocking exhaustion? iayork.comIcebrg-3/23/2009
2130Overexpression of PD-L1 significantly associates with tumor aggressiveness and pIcebrg-3/22/2009
2129Could be some fallout to MEDX on the Merck/SGP merger wrt to golimumab franchisetuck-3/10/2009
2128Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by CombiIcebrg-3/1/2009
2127Upcoming events as per UBS as per company as per Yahoo! post. messages.finance.Icebrg-2/26/2009
2126Popular piece on the immune system and cancer: forbes.comA.J. Mullen-2/20/2009
2125Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-StimulatinIcebrg-2/13/2009
2124Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and PIcebrg-2/5/2009
2123Item 5.02. Departure of Directors or Certain Officers; Election of Directors; ApIcebrg-2/4/2009
2122Medarex to Receive Milestone Payment from MedImmune for Allowance of an InvestigIcebrg-2/2/2009
2121In their Q4 report Novartis says they have filed for approval of ACZ885 for the Icebrg-1/28/2009
2120Medarex Announces Allowance of Investigational New Drug Application for Company&Icebrg-1/28/2009
2119New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate tIcebrg-1/22/2009
2118In the 4 Qtr Earnings CC J&J said:<i> Regarding Ustekinumab we have suIcebrg-1/21/2009
2117Celldex Announces License of its Cholera and ETEC Vaccine Programs NEEDHAM, MasIcebrg-1/20/2009
2116A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Icebrg-1/19/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News